$BCRX
BIOCRYST PHARMACEUTICALS INC

2017 Q4 Form 10-K Financial Statement

#000117184318001855 Filed on March 12, 2018

View on sec.gov

Income Statement

Concept 2017 Q4 2017 2016 Q4
Revenue $3.890M $25.19M $8.983M
YoY Change -56.7% -4.43% 95.2%
Cost Of Revenue $130.0K $1.142M $2.450M
YoY Change -94.69% -50.28% 8066.67%
Gross Profit $3.760M $24.04M $6.530M
YoY Change -42.42% -0.05% 42.89%
Gross Profit Margin 96.66% 95.47% 72.69%
Selling, General & Admin $4.700M $13.93M $2.560M
YoY Change 83.59% 23.82% -5.88%
% of Gross Profit 125.0% 57.95% 39.2%
Research & Development $16.92M $66.96M $12.16M
YoY Change 39.14% 9.76% -36.17%
% of Gross Profit 450.0% 278.5% 186.22%
Depreciation & Amortization $180.0K $704.0K $170.0K
YoY Change 5.88% 45.76% 325.0%
% of Gross Profit 4.79% 2.93% 2.6%
Operating Expenses $21.62M $80.90M $14.72M
YoY Change 46.88% 11.95% -32.38%
Operating Profit -$17.86M -$57.41M -$8.190M
YoY Change 118.07% 18.11% -52.38%
Interest Expense -$1.680M $8.565M $3.690M
YoY Change -145.53% 32.03% -492.55%
% of Operating Profit
Other Income/Expense, Net
YoY Change
Pretax Income -$19.54M -$65.78M -$4.500M
YoY Change 334.22% 19.3% -75.19%
Income Tax $0.00 $0.00
% Of Pretax Income
Net Earnings -$19.54M -$65.78M -$4.503M
YoY Change 334.0% 19.29% -75.17%
Net Earnings / Revenue -502.39% -261.18% -50.13%
Basic Earnings Per Share
Diluted Earnings Per Share -$198.3K -$778.9K -$61.00K
COMMON SHARES
Basic Shares Outstanding
Diluted Shares Outstanding 84.45M

Balance Sheet

Concept 2017 Q4 2017 2016 Q4
SHORT-TERM ASSETS
Cash & Short-Term Investments $114.4M $114.4M $54.65M
YoY Change 109.33% 109.14% 5.99%
Cash & Equivalents $50.28M $50.30M $22.10M
Short-Term Investments $64.12M $64.10M $32.55M
Other Short-Term Assets $4.900M $4.900M $3.000M
YoY Change 63.33% 63.33% -31.82%
Inventory $500.0K
Prepaid Expenses
Receivables $6.117M $6.100M $8.768M
Other Receivables $0.00 $0.00 $0.00
Total Short-Term Assets $125.4M $125.4M $66.99M
YoY Change 87.19% 87.16% 5.01%
LONG-TERM ASSETS
Property, Plant & Equipment $9.546M $9.500M $9.922M
YoY Change -3.79% -4.04% 92.7%
Goodwill
YoY Change
Intangibles
YoY Change
Long-Term Investments $41.30M $41.30M $8.900M
YoY Change 364.04% 364.04% -81.34%
Other Assets $2.027M $2.000M $3.813M
YoY Change -46.84% -50.0% -30.27%
Total Long-Term Assets $52.87M $52.90M $22.86M
YoY Change 131.27% 132.02% -60.97%
TOTAL ASSETS
Total Short-Term Assets $125.4M $125.4M $66.99M
Total Long-Term Assets $52.87M $52.90M $22.86M
Total Assets $178.3M $178.3M $89.85M
YoY Change 98.4% 98.55% -26.57%
SHORT-TERM LIABILITIES
YoY Change
Accounts Payable $6.337M $6.300M $4.269M
YoY Change 48.44% 46.51% -54.13%
Accrued Expenses $12.70M $24.80M $10.84M
YoY Change 17.19% 25.25% -33.26%
Deferred Revenue
YoY Change
Short-Term Debt $28.70M $28.70M $28.20M
YoY Change 1.77% 1.77% 1.44%
Long-Term Debt Due $6.500M $6.500M
YoY Change
Total Short-Term Liabilities $74.84M $74.80M $54.36M
YoY Change 37.67% 37.5% -12.68%
LONG-TERM LIABILITIES
Long-Term Debt $19.50M $19.50M $25.50M
YoY Change -23.53% -23.53% 962.5%
Other Long-Term Liabilities $200.0K $200.0K $8.400M
YoY Change -97.62% -97.62% -16.0%
Total Long-Term Liabilities $19.70M $19.70M $33.90M
YoY Change -41.89% -41.89% 173.39%
TOTAL LIABILITIES
Total Short-Term Liabilities $74.84M $74.80M $54.36M
Total Long-Term Liabilities $19.70M $19.70M $33.90M
Total Liabilities $94.50M $94.50M $88.30M
YoY Change 7.02% 7.02% 18.36%
SHAREHOLDERS EQUITY
Retained Earnings -$631.8M -$566.1M
YoY Change 11.62% 10.79%
Common Stock $984.0K $738.0K
YoY Change 33.33% 0.54%
Preferred Stock
YoY Change
Treasury Stock (at cost)
YoY Change
Treasury Stock Shares
Shareholders Equity $83.77M $83.80M $1.578M
YoY Change
Total Liabilities & Shareholders Equity $178.3M $178.3M $89.85M
YoY Change 98.4% 98.55% -26.57%

Cashflow Statement

Concept 2017 Q4 2017 2016 Q4
OPERATING ACTIVITIES
Net Income -$19.54M -$65.78M -$4.503M
YoY Change 334.0% 19.29% -75.17%
Depreciation, Depletion And Amortization $180.0K $704.0K $170.0K
YoY Change 5.88% 45.76% 325.0%
Cash From Operating Activities -$10.52M -$41.14M -$5.860M
YoY Change 79.52% -23.01% -60.49%
INVESTING ACTIVITIES
Capital Expenditures -$120.0K $328.0K $0.00
YoY Change -106.21% -100.0%
Acquisitions
YoY Change
Other Investing Activities -$55.69M -$64.31M -$9.830M
YoY Change 466.53% -325.25% -1027.36%
Cash From Investing Activities -$55.81M -$64.64M -$9.830M
YoY Change 467.75% -377.76% 229.87%
FINANCING ACTIVITIES
Cash Dividend Paid
YoY Change
Common Stock Issuance & Retirement, Net $134.0M
YoY Change
Debt Paid & Issued, Net
YoY Change
Cash From Financing Activities 570.0K 135.7M 2.330M
YoY Change -75.54% 482.32% 2488.89%
NET CHANGE
Cash From Operating Activities -10.52M -41.14M -5.860M
Cash From Investing Activities -55.81M -64.64M -9.830M
Cash From Financing Activities 570.0K 135.7M 2.330M
Net Change In Cash -65.76M 29.92M -13.36M
YoY Change 392.22% -536.06% -24.6%
FREE CASH FLOW
Cash From Operating Activities -$10.52M -$41.14M -$5.860M
Capital Expenditures -$120.0K $328.0K $0.00
Free Cash Flow -$10.40M -$41.47M -$5.860M
YoY Change 77.47% -13.89% -45.69%

Facts In Submission

Frame Concept Type Concept / XBRL Key Value Unit
CY2017Q4 bcrx Accrued Development Costs
AccruedDevelopmentCosts
6683000
CY2016Q4 bcrx Accrued Development Costs
AccruedDevelopmentCosts
7427000
CY2017Q4 bcrx Accrued Inventory Expense
AccruedInventoryExpense
CY2016Q4 bcrx Accrued Inventory Expense
AccruedInventoryExpense
705000
CY2017 bcrx Amortization Of Discount And Premium On Investments
AmortizationOfDiscountAndPremiumOnInvestments
157000
CY2016 bcrx Amortization Of Discount And Premium On Investments
AmortizationOfDiscountAndPremiumOnInvestments
523000
CY2015 bcrx Amortization Of Discount And Premium On Investments
AmortizationOfDiscountAndPremiumOnInvestments
570000
CY2017Q4 bcrx Available For Sale Securities Accrued Interest
AvailableForSaleSecuritiesAccruedInterest
412000
CY2016Q4 bcrx Available For Sale Securities Accrued Interest
AvailableForSaleSecuritiesAccruedInterest
77000
CY2017Q4 bcrx Available For Sale Securities Debt Maturities After One Through Two Years Fair Value
AvailableForSaleSecuritiesDebtMaturitiesAfterOneThroughTwoYearsFairValue
34257000
CY2016Q4 bcrx Available For Sale Securities Debt Maturities After One Through Two Years Fair Value
AvailableForSaleSecuritiesDebtMaturitiesAfterOneThroughTwoYearsFairValue
8926000
CY2017Q4 bcrx Available For Sale Securities Debt Maturities Maturing After Two Years
AvailableForSaleSecuritiesDebtMaturitiesMaturingAfterTwoYears
7038000
CY2016Q4 bcrx Available For Sale Securities Debt Maturities Maturing After Two Years
AvailableForSaleSecuritiesDebtMaturitiesMaturingAfterTwoYears
CY2007Q1 bcrx Collaborative Agreement Contract Value
CollaborativeAgreementContractValue
5000000
CY2017 bcrx Collaborative And Other Research And Development
CollaborativeAndOtherResearchAndDevelopment
13142000
CY2016 bcrx Collaborative And Other Research And Development
CollaborativeAndOtherResearchAndDevelopment
14402000
CY2015 bcrx Collaborative And Other Research And Development
CollaborativeAndOtherResearchAndDevelopment
39580000
CY2017 bcrx Collaborative And Other Research And Development Revenues
CollaborativeAndOtherResearchAndDevelopmentRevenues
13142000
CY2016 bcrx Collaborative And Other Research And Development Revenues
CollaborativeAndOtherResearchAndDevelopmentRevenues
14402000
CY2015 bcrx Collaborative And Other Research And Development Revenues
CollaborativeAndOtherResearchAndDevelopmentRevenues
39580000
CY2017Q4 bcrx Deferred Collaboration Expense Assets
DeferredCollaborationExpenseAssets
CY2016Q4 bcrx Deferred Collaboration Expense Assets
DeferredCollaborationExpenseAssets
199000
CY2017 bcrx Deferred Collaboration Expense Changes In Operating Assets And Liabilities
DeferredCollaborationExpenseChangesInOperatingAssetsAndLiabilities
-74000
CY2016 bcrx Deferred Collaboration Expense Changes In Operating Assets And Liabilities
DeferredCollaborationExpenseChangesInOperatingAssetsAndLiabilities
-71000
CY2015 bcrx Deferred Collaboration Expense Changes In Operating Assets And Liabilities
DeferredCollaborationExpenseChangesInOperatingAssetsAndLiabilities
102000
CY2017 bcrx Effective Income Tax Rate Reconciliation Tax Credit Orphan Drug Amount
EffectiveIncomeTaxRateReconciliationTaxCreditOrphanDrugAmount
564000
CY2016 bcrx Effective Income Tax Rate Reconciliation Tax Credit Orphan Drug Amount
EffectiveIncomeTaxRateReconciliationTaxCreditOrphanDrugAmount
1798000
CY2015 bcrx Effective Income Tax Rate Reconciliation Tax Credit Orphan Drug Amount
EffectiveIncomeTaxRateReconciliationTaxCreditOrphanDrugAmount
4307000
CY2017Q4 bcrx Employee Service Share Based Compensation Nonvested Awards Compensation Cost Expected To Be Recognized Year Four
EmployeeServiceShareBasedCompensationNonvestedAwardsCompensationCostExpectedToBeRecognizedYearFour
1361000
CY2017Q4 bcrx Employee Service Share Based Compensation Nonvested Awards Compensation Cost Expected To Be Recognized Year Three
EmployeeServiceShareBasedCompensationNonvestedAwardsCompensationCostExpectedToBeRecognizedYearThree
3365000
CY2017Q4 bcrx Employee Service Share Based Compensation Nonvested Awards Compensation Cost Expected To Be Recognized Year Two
EmployeeServiceShareBasedCompensationNonvestedAwardsCompensationCostExpectedToBeRecognizedYearTwo
5452000
CY2017Q4 bcrx Employee Service Sharebased Compensation Nonvested Awards Compensation Cost Expected To Be Recognized Next Year
EmployeeServiceSharebasedCompensationNonvestedAwardsCompensationCostExpectedToBeRecognizedNextYear
7607000
CY2017 bcrx Income Tax Rate Reconciliation Adoption Of Accounting Standards Update Amount
IncomeTaxRateReconciliationAdoptionOfAccountingStandardsUpdateAmount
5949000
CY2016 bcrx Income Tax Rate Reconciliation Adoption Of Accounting Standards Update Amount
IncomeTaxRateReconciliationAdoptionOfAccountingStandardsUpdateAmount
CY2015 bcrx Income Tax Rate Reconciliation Adoption Of Accounting Standards Update Amount
IncomeTaxRateReconciliationAdoptionOfAccountingStandardsUpdateAmount
CY2017 bcrx Income Tax Reconciliation Income Tax Expense Benefit Expiration Of Carry Forwards
IncomeTaxReconciliationIncomeTaxExpenseBenefitExpirationOfCarryForwards
918000
CY2016 bcrx Income Tax Reconciliation Income Tax Expense Benefit Expiration Of Carry Forwards
IncomeTaxReconciliationIncomeTaxExpenseBenefitExpirationOfCarryForwards
559000
CY2015 bcrx Income Tax Reconciliation Income Tax Expense Benefit Expiration Of Carry Forwards
IncomeTaxReconciliationIncomeTaxExpenseBenefitExpirationOfCarryForwards
330000
CY2017 bcrx Increase Decrease In Financing Lease Obligations
IncreaseDecreaseInFinancingLeaseObligations
122000
CY2016 bcrx Increase Decrease In Financing Lease Obligations
IncreaseDecreaseInFinancingLeaseObligations
329000
CY2015 bcrx Increase Decrease In Financing Lease Obligations
IncreaseDecreaseInFinancingLeaseObligations
CY2017Q4 bcrx Lease Financing Obligation Net Of Current
LeaseFinancingObligationNetOfCurrent
2751000
CY2016Q4 bcrx Lease Financing Obligation Net Of Current
LeaseFinancingObligationNetOfCurrent
2704000
CY2017Q4 bcrx Maximum Aggregate Offering Price
MaximumAggregateOfferingPrice
200000000
CY2017 bcrx Number Of Stockbased Compensation Plans
NumberOfStockbasedCompensationPlans
2
CY2017Q4 us-gaap Accounts Payable Current
AccountsPayableCurrent
6337000
CY2016Q4 us-gaap Accounts Payable Current
AccountsPayableCurrent
4269000
CY2017Q4 us-gaap Accounts Receivable Net Current
AccountsReceivableNetCurrent
6117000
CY2016Q4 us-gaap Accounts Receivable Net Current
AccountsReceivableNetCurrent
8768000
CY2017Q4 us-gaap Accrued Liabilities Current
AccruedLiabilitiesCurrent
12699000
CY2016Q4 us-gaap Accrued Liabilities Current
AccruedLiabilitiesCurrent
10836000
CY2016 us-gaap Allocated Share Based Compensation Expense
AllocatedShareBasedCompensationExpense
8487000
CY2017Q4 us-gaap Accrued Professional Fees Current
AccruedProfessionalFeesCurrent
729000
CY2016Q4 us-gaap Accrued Professional Fees Current
AccruedProfessionalFeesCurrent
242000
CY2017Q4 us-gaap Accumulated Depreciation Depletion And Amortization Property Plant And Equipment
AccumulatedDepreciationDepletionAndAmortizationPropertyPlantAndEquipment
5327000
CY2016Q4 us-gaap Accumulated Depreciation Depletion And Amortization Property Plant And Equipment
AccumulatedDepreciationDepletionAndAmortizationPropertyPlantAndEquipment
4917000
CY2017Q4 us-gaap Accumulated Other Comprehensive Income Loss Net Of Tax
AccumulatedOtherComprehensiveIncomeLossNetOfTax
-243000
CY2016Q4 us-gaap Accumulated Other Comprehensive Income Loss Net Of Tax
AccumulatedOtherComprehensiveIncomeLossNetOfTax
-12000
CY2017Q4 us-gaap Additional Paid In Capital
AdditionalPaidInCapital
714869000
CY2016Q4 us-gaap Additional Paid In Capital
AdditionalPaidInCapital
566913000
CY2017 us-gaap Amortization Of Financing Costs
AmortizationOfFinancingCosts
876000
CY2015 us-gaap Adjustments To Additional Paid In Capital Sharebased Compensation Requisite Service Period Recognition Value
AdjustmentsToAdditionalPaidInCapitalSharebasedCompensationRequisiteServicePeriodRecognitionValue
9705000
CY2016 us-gaap Adjustments To Additional Paid In Capital Sharebased Compensation Requisite Service Period Recognition Value
AdjustmentsToAdditionalPaidInCapitalSharebasedCompensationRequisiteServicePeriodRecognitionValue
8487000
CY2017 us-gaap Adjustments To Additional Paid In Capital Sharebased Compensation Requisite Service Period Recognition Value
AdjustmentsToAdditionalPaidInCapitalSharebasedCompensationRequisiteServicePeriodRecognitionValue
12621000
CY2015 us-gaap Advertising Expense
AdvertisingExpense
103000
CY2017 us-gaap Advertising Expense
AdvertisingExpense
0
CY2016 us-gaap Advertising Expense
AdvertisingExpense
0
CY2017 us-gaap Allocated Share Based Compensation Expense
AllocatedShareBasedCompensationExpense
12621000
CY2015 us-gaap Allocated Share Based Compensation Expense
AllocatedShareBasedCompensationExpense
9705000
CY2017Q4 us-gaap Available For Sale Securities Debt Maturities Within One Year Fair Value
AvailableForSaleSecuritiesDebtMaturitiesWithinOneYearFairValue
64115000
CY2016Q4 us-gaap Available For Sale Securities Debt Maturities Within One Year Fair Value
AvailableForSaleSecuritiesDebtMaturitiesWithinOneYearFairValue
32546000
CY2017Q4 us-gaap Available For Sale Securities Debt Securities Current
AvailableForSaleSecuritiesDebtSecuritiesCurrent
64115000
CY2016Q4 us-gaap Available For Sale Securities Debt Securities Current
AvailableForSaleSecuritiesDebtSecuritiesCurrent
32546000
CY2017Q4 us-gaap Available For Sale Securities Debt Securities Noncurrent
AvailableForSaleSecuritiesDebtSecuritiesNoncurrent
41295000
CY2016Q4 us-gaap Available For Sale Securities Debt Securities Noncurrent
AvailableForSaleSecuritiesDebtSecuritiesNoncurrent
8926000
CY2016 us-gaap Amortization Of Financing Costs
AmortizationOfFinancingCosts
558000
CY2015 us-gaap Amortization Of Financing Costs
AmortizationOfFinancingCosts
439000
CY2017 us-gaap Antidilutive Securities Excluded From Computation Of Earnings Per Share Amount
AntidilutiveSecuritiesExcludedFromComputationOfEarningsPerShareAmount
2067000
CY2016 us-gaap Antidilutive Securities Excluded From Computation Of Earnings Per Share Amount
AntidilutiveSecuritiesExcludedFromComputationOfEarningsPerShareAmount
1226000
CY2015 us-gaap Antidilutive Securities Excluded From Computation Of Earnings Per Share Amount
AntidilutiveSecuritiesExcludedFromComputationOfEarningsPerShareAmount
3524000
CY2017Q4 us-gaap Assets
Assets
178259000
CY2016Q4 us-gaap Assets
Assets
89847000
CY2017Q4 us-gaap Assets Current
AssetsCurrent
125391000
CY2016Q4 us-gaap Assets Current
AssetsCurrent
66987000
CY2017Q4 us-gaap Available For Sale Securities
AvailableForSaleSecurities
105410000
CY2016Q4 us-gaap Available For Sale Securities
AvailableForSaleSecurities
41472000
CY2017Q4 us-gaap Available For Sale Securities Accumulated Gross Unrealized Gain Before Tax
AvailableForSaleSecuritiesAccumulatedGrossUnrealizedGainBeforeTax
1000
CY2016Q4 us-gaap Available For Sale Securities Accumulated Gross Unrealized Gain Before Tax
AvailableForSaleSecuritiesAccumulatedGrossUnrealizedGainBeforeTax
11000
CY2017Q4 us-gaap Available For Sale Securities Accumulated Gross Unrealized Loss Before Tax
AvailableForSaleSecuritiesAccumulatedGrossUnrealizedLossBeforeTax
244000
CY2016Q4 us-gaap Available For Sale Securities Accumulated Gross Unrealized Loss Before Tax
AvailableForSaleSecuritiesAccumulatedGrossUnrealizedLossBeforeTax
23000
CY2017Q4 us-gaap Available For Sale Securities Amortized Cost
AvailableForSaleSecuritiesAmortizedCost
105241000
CY2016Q4 us-gaap Available For Sale Securities Amortized Cost
AvailableForSaleSecuritiesAmortizedCost
41407000
CY2017Q4 us-gaap Capital Lease Obligations Current
CapitalLeaseObligationsCurrent
75000
CY2016Q4 us-gaap Capital Lease Obligations Current
CapitalLeaseObligationsCurrent
CY2017Q4 us-gaap Cash And Cash Equivalents At Carrying Value
CashAndCashEquivalentsAtCarryingValue
50282000
CY2016Q4 us-gaap Cash And Cash Equivalents At Carrying Value
CashAndCashEquivalentsAtCarryingValue
22104000
CY2015Q4 us-gaap Cash And Cash Equivalents At Carrying Value
CashAndCashEquivalentsAtCarryingValue
28899000
CY2014Q4 us-gaap Cash And Cash Equivalents At Carrying Value
CashAndCashEquivalentsAtCarryingValue
54540000
CY2017 us-gaap Cash And Cash Equivalents Period Increase Decrease
CashAndCashEquivalentsPeriodIncreaseDecrease
28178000
CY2016 us-gaap Cash And Cash Equivalents Period Increase Decrease
CashAndCashEquivalentsPeriodIncreaseDecrease
-6795000
CY2015 us-gaap Cash And Cash Equivalents Period Increase Decrease
CashAndCashEquivalentsPeriodIncreaseDecrease
-25641000
CY2017Q4 us-gaap Common Stock Shares Issued
CommonStockSharesIssued
98411000
CY2016Q4 us-gaap Common Stock Shares Issued
CommonStockSharesIssued
73782000
CY2017Q4 us-gaap Common Stock Par Or Stated Value Per Share
CommonStockParOrStatedValuePerShare
0.01
CY2016Q4 us-gaap Common Stock Par Or Stated Value Per Share
CommonStockParOrStatedValuePerShare
0.01
CY2017Q4 us-gaap Common Stock Shares Authorized
CommonStockSharesAuthorized
200000000
CY2016Q4 us-gaap Common Stock Shares Authorized
CommonStockSharesAuthorized
200000000
CY2017Q4 us-gaap Common Stock Shares Outstanding
CommonStockSharesOutstanding
98411000
CY2016Q4 us-gaap Common Stock Shares Outstanding
CommonStockSharesOutstanding
73782000
CY2017Q4 us-gaap Common Stock Value
CommonStockValue
984000
CY2016Q4 us-gaap Common Stock Value
CommonStockValue
738000
CY2017 us-gaap Comprehensive Income Net Of Tax
ComprehensiveIncomeNetOfTax
-66013000
CY2016 us-gaap Comprehensive Income Net Of Tax
ComprehensiveIncomeNetOfTax
-54950000
CY2015 us-gaap Comprehensive Income Net Of Tax
ComprehensiveIncomeNetOfTax
-43095000
CY2017 us-gaap Cost Of Goods Sold
CostOfGoodsSold
1142000
CY2016 us-gaap Cost Of Goods Sold
CostOfGoodsSold
2297000
CY2015 us-gaap Cost Of Goods Sold
CostOfGoodsSold
1368000
CY2017 us-gaap Costs And Expenses
CostsAndExpenses
82597000
CY2016 us-gaap Costs And Expenses
CostsAndExpenses
74960000
CY2015 us-gaap Costs And Expenses
CostsAndExpenses
87701000
CY2017Q4 us-gaap Deferred Costs Current
DeferredCostsCurrent
210000
CY2016Q4 us-gaap Deferred Costs Current
DeferredCostsCurrent
85000
CY2017Q4 us-gaap Deferred Income Tax Liabilities
DeferredIncomeTaxLiabilities
899000
CY2016Q4 us-gaap Deferred Income Tax Liabilities
DeferredIncomeTaxLiabilities
2089000
CY2017Q4 us-gaap Deferred Rent Credit Noncurrent
DeferredRentCreditNoncurrent
155000
CY2016Q4 us-gaap Deferred Rent Credit Noncurrent
DeferredRentCreditNoncurrent
244000
CY2017Q4 us-gaap Deferred Revenue Current
DeferredRevenueCurrent
8484000
CY2016Q4 us-gaap Deferred Revenue Current
DeferredRevenueCurrent
2022000
CY2017Q4 us-gaap Deferred Revenue Noncurrent
DeferredRevenueNoncurrent
CY2016Q4 us-gaap Deferred Revenue Noncurrent
DeferredRevenueNoncurrent
8184000
CY2017Q4 us-gaap Deferred Tax Assets Deferred Income
DeferredTaxAssetsDeferredIncome
1854000
CY2016Q4 us-gaap Deferred Tax Assets Deferred Income
DeferredTaxAssetsDeferredIncome
3484000
CY2017Q4 us-gaap Deferred Tax Assets Gross
DeferredTaxAssetsGross
183319000
CY2016Q4 us-gaap Deferred Tax Assets Gross
DeferredTaxAssetsGross
227134000
CY2017Q4 us-gaap Deferred Tax Assets Liabilities Net
DeferredTaxAssetsLiabilitiesNet
CY2016Q4 us-gaap Deferred Tax Assets Liabilities Net
DeferredTaxAssetsLiabilitiesNet
CY2017Q4 us-gaap Deferred Tax Assets Operating Loss Carryforwards Domestic
DeferredTaxAssetsOperatingLossCarryforwardsDomestic
117787000
CY2016Q4 us-gaap Deferred Tax Assets Operating Loss Carryforwards Domestic
DeferredTaxAssetsOperatingLossCarryforwardsDomestic
158618000
CY2017Q4 us-gaap Deferred Tax Assets Other
DeferredTaxAssetsOther
2046000
CY2016Q4 us-gaap Deferred Tax Assets Other
DeferredTaxAssetsOther
2849000
CY2017Q4 us-gaap Deferred Tax Assets Tax Credit Carryforwards Research
DeferredTaxAssetsTaxCreditCarryforwardsResearch
55208000
CY2016Q4 us-gaap Deferred Tax Assets Tax Credit Carryforwards Research
DeferredTaxAssetsTaxCreditCarryforwardsResearch
53231000
CY2017Q4 us-gaap Deferred Tax Assets Tax Deferred Expense Compensation And Benefits Share Based Compensation Cost
DeferredTaxAssetsTaxDeferredExpenseCompensationAndBenefitsShareBasedCompensationCost
6424000
CY2016Q4 us-gaap Deferred Tax Assets Tax Deferred Expense Compensation And Benefits Share Based Compensation Cost
DeferredTaxAssetsTaxDeferredExpenseCompensationAndBenefitsShareBasedCompensationCost
8952000
CY2017Q4 us-gaap Deferred Tax Assets Valuation Allowance
DeferredTaxAssetsValuationAllowance
182420000
CY2016Q4 us-gaap Deferred Tax Assets Valuation Allowance
DeferredTaxAssetsValuationAllowance
225045000
CY2017Q4 us-gaap Deferred Tax Liabilities Property Plant And Equipment
DeferredTaxLiabilitiesPropertyPlantAndEquipment
421000
CY2016Q4 us-gaap Deferred Tax Liabilities Property Plant And Equipment
DeferredTaxLiabilitiesPropertyPlantAndEquipment
674000
CY2017Q4 us-gaap Deferred Tax Liabilities Unrealized Currency Transaction Gains
DeferredTaxLiabilitiesUnrealizedCurrencyTransactionGains
478000
CY2016Q4 us-gaap Deferred Tax Liabilities Unrealized Currency Transaction Gains
DeferredTaxLiabilitiesUnrealizedCurrencyTransactionGains
1415000
CY2017 us-gaap Defined Contribution Plan Employer Discretionary Contribution Amount
DefinedContributionPlanEmployerDiscretionaryContributionAmount
664000
CY2016 us-gaap Defined Contribution Plan Employer Discretionary Contribution Amount
DefinedContributionPlanEmployerDiscretionaryContributionAmount
504000
CY2015 us-gaap Defined Contribution Plan Employer Discretionary Contribution Amount
DefinedContributionPlanEmployerDiscretionaryContributionAmount
366000
CY2017 us-gaap Depreciation Depletion And Amortization
DepreciationDepletionAndAmortization
704000
CY2016 us-gaap Depreciation Depletion And Amortization
DepreciationDepletionAndAmortization
483000
CY2015 us-gaap Depreciation Depletion And Amortization
DepreciationDepletionAndAmortization
180000
CY2017 us-gaap Earnings Per Share Basic And Diluted
EarningsPerShareBasicAndDiluted
-0.78
CY2016 us-gaap Earnings Per Share Basic And Diluted
EarningsPerShareBasicAndDiluted
-0.75
CY2015 us-gaap Earnings Per Share Basic And Diluted
EarningsPerShareBasicAndDiluted
-0.59
CY2017Q1 us-gaap Earnings Per Share Basic And Diluted
EarningsPerShareBasicAndDiluted
-0.19
CY2017Q2 us-gaap Earnings Per Share Basic And Diluted
EarningsPerShareBasicAndDiluted
-0.21
CY2017Q4 us-gaap Income Tax Expense Benefit Continuing Operations Adjustment Of Deferred Tax Asset Liability
IncomeTaxExpenseBenefitContinuingOperationsAdjustmentOfDeferredTaxAssetLiability
73474000000
CY2017Q3 us-gaap Earnings Per Share Basic And Diluted
EarningsPerShareBasicAndDiluted
-0.18
CY2017Q4 us-gaap Earnings Per Share Basic And Diluted
EarningsPerShareBasicAndDiluted
-0.20
CY2016Q1 us-gaap Earnings Per Share Basic And Diluted
EarningsPerShareBasicAndDiluted
-0.31
CY2016Q2 us-gaap Earnings Per Share Basic And Diluted
EarningsPerShareBasicAndDiluted
-0.22
CY2016Q3 us-gaap Earnings Per Share Basic And Diluted
EarningsPerShareBasicAndDiluted
-0.16
CY2016Q4 us-gaap Earnings Per Share Basic And Diluted
EarningsPerShareBasicAndDiluted
-0.06
CY2015 us-gaap Gain Loss On Disposition Of Assets1
GainLossOnDispositionOfAssets1
CY2017 us-gaap Gain Loss On Foreign Currency Derivative Instruments Not Designated As Hedging Instruments
GainLossOnForeignCurrencyDerivativeInstrumentsNotDesignatedAsHedgingInstruments
-821000
CY2016 us-gaap Gain Loss On Foreign Currency Derivative Instruments Not Designated As Hedging Instruments
GainLossOnForeignCurrencyDerivativeInstrumentsNotDesignatedAsHedgingInstruments
-843000
CY2015 us-gaap Gain Loss On Foreign Currency Derivative Instruments Not Designated As Hedging Instruments
GainLossOnForeignCurrencyDerivativeInstrumentsNotDesignatedAsHedgingInstruments
1090000
CY2017 us-gaap Income Tax Expense Benefit
IncomeTaxExpenseBenefit
0
CY2016 us-gaap Income Tax Expense Benefit
IncomeTaxExpenseBenefit
0
CY2015 us-gaap Income Tax Expense Benefit
IncomeTaxExpenseBenefit
0
CY2017 us-gaap Effective Income Tax Rate Reconciliation At Federal Statutory Income Tax Rate
EffectiveIncomeTaxRateReconciliationAtFederalStatutoryIncomeTaxRate
0.35
CY2017Q4 us-gaap Employee Related Liabilities Current
EmployeeRelatedLiabilitiesCurrent
2905000
CY2016Q4 us-gaap Employee Related Liabilities Current
EmployeeRelatedLiabilitiesCurrent
425000
CY2017Q4 us-gaap Employee Service Share Based Compensation Nonvested Awards Total Compensation Cost Not Yet Recognized
EmployeeServiceShareBasedCompensationNonvestedAwardsTotalCompensationCostNotYetRecognized
17785000
CY2017 us-gaap Gain Loss On Disposition Of Assets1
GainLossOnDispositionOfAssets1
12000
CY2016 us-gaap Gain Loss On Disposition Of Assets1
GainLossOnDispositionOfAssets1
-17000
CY2017 us-gaap Income Tax Reconciliation Change In Deferred Tax Assets Valuation Allowance
IncomeTaxReconciliationChangeInDeferredTaxAssetsValuationAllowance
-42625000
CY2016 us-gaap Income Tax Reconciliation Change In Deferred Tax Assets Valuation Allowance
IncomeTaxReconciliationChangeInDeferredTaxAssetsValuationAllowance
19838000
CY2015 us-gaap Income Tax Reconciliation Change In Deferred Tax Assets Valuation Allowance
IncomeTaxReconciliationChangeInDeferredTaxAssetsValuationAllowance
20339000
CY2017 us-gaap Income Tax Reconciliation Change In Enacted Tax Rate
IncomeTaxReconciliationChangeInEnactedTaxRate
71155000
CY2016 us-gaap Income Tax Reconciliation Change In Enacted Tax Rate
IncomeTaxReconciliationChangeInEnactedTaxRate
1080000
CY2015 us-gaap Income Tax Reconciliation Change In Enacted Tax Rate
IncomeTaxReconciliationChangeInEnactedTaxRate
1012000
CY2017 us-gaap Income Tax Reconciliation Income Tax Expense Benefit At Federal Statutory Income Tax Rate
IncomeTaxReconciliationIncomeTaxExpenseBenefitAtFederalStatutoryIncomeTaxRate
-23024000
CY2016 us-gaap Income Tax Reconciliation Income Tax Expense Benefit At Federal Statutory Income Tax Rate
IncomeTaxReconciliationIncomeTaxExpenseBenefitAtFederalStatutoryIncomeTaxRate
-19300000
CY2015 us-gaap Income Tax Reconciliation Income Tax Expense Benefit At Federal Statutory Income Tax Rate
IncomeTaxReconciliationIncomeTaxExpenseBenefitAtFederalStatutoryIncomeTaxRate
-15057000
CY2017 us-gaap Income Tax Reconciliation Nondeductible Expense
IncomeTaxReconciliationNondeductibleExpense
910000
CY2016 us-gaap Income Tax Reconciliation Nondeductible Expense
IncomeTaxReconciliationNondeductibleExpense
1057000
CY2015 us-gaap Income Tax Reconciliation Nondeductible Expense
IncomeTaxReconciliationNondeductibleExpense
560000
CY2017 us-gaap Income Tax Reconciliation Other Adjustments
IncomeTaxReconciliationOtherAdjustments
1639000
CY2016 us-gaap Income Tax Reconciliation Other Adjustments
IncomeTaxReconciliationOtherAdjustments
822000
CY2015 us-gaap Income Tax Reconciliation Other Adjustments
IncomeTaxReconciliationOtherAdjustments
-218000
CY2017 us-gaap Income Tax Reconciliation State And Local Income Taxes
IncomeTaxReconciliationStateAndLocalIncomeTaxes
-1611000
CY2016 us-gaap Income Tax Reconciliation State And Local Income Taxes
IncomeTaxReconciliationStateAndLocalIncomeTaxes
-1173000
CY2015 us-gaap Income Tax Reconciliation State And Local Income Taxes
IncomeTaxReconciliationStateAndLocalIncomeTaxes
-819000
CY2017 us-gaap Income Tax Reconciliation Tax Credits Research
IncomeTaxReconciliationTaxCreditsResearch
1977000
CY2016 us-gaap Income Tax Reconciliation Tax Credits Research
IncomeTaxReconciliationTaxCreditsResearch
4681000
CY2015 us-gaap Income Tax Reconciliation Tax Credits Research
IncomeTaxReconciliationTaxCreditsResearch
10454000
CY2017 us-gaap Increase Decrease In Accounts Payable
IncreaseDecreaseInAccountsPayable
3842000
CY2016 us-gaap Increase Decrease In Accounts Payable
IncreaseDecreaseInAccountsPayable
-10524000
CY2015 us-gaap Increase Decrease In Accounts Payable
IncreaseDecreaseInAccountsPayable
13676000
CY2017 us-gaap Increase Decrease In Deferred Revenue
IncreaseDecreaseInDeferredRevenue
-1722000
CY2016 us-gaap Increase Decrease In Deferred Revenue
IncreaseDecreaseInDeferredRevenue
-1631000
CY2015 us-gaap Increase Decrease In Deferred Revenue
IncreaseDecreaseInDeferredRevenue
1199000
CY2017 us-gaap Increase Decrease In Derivative Assets
IncreaseDecreaseInDerivativeAssets
-966000
CY2016 us-gaap Increase Decrease In Derivative Assets
IncreaseDecreaseInDerivativeAssets
811000
CY2015 us-gaap Increase Decrease In Derivative Assets
IncreaseDecreaseInDerivativeAssets
-564000
CY2017 us-gaap Increase Decrease In Interest Payable Net
IncreaseDecreaseInInterestPayableNet
3105000
CY2016 us-gaap Increase Decrease In Interest Payable Net
IncreaseDecreaseInInterestPayableNet
2244000
CY2015 us-gaap Increase Decrease In Interest Payable Net
IncreaseDecreaseInInterestPayableNet
717000
CY2017 us-gaap Increase Decrease In Inventories
IncreaseDecreaseInInventories
-500000
CY2016 us-gaap Increase Decrease In Inventories
IncreaseDecreaseInInventories
-1112000
CY2015 us-gaap Increase Decrease In Inventories
IncreaseDecreaseInInventories
929000
CY2017 us-gaap Increase Decrease In Prepaid Deferred Expense And Other Assets
IncreaseDecreaseInPrepaidDeferredExpenseAndOtherAssets
-877000
CY2016 us-gaap Increase Decrease In Prepaid Deferred Expense And Other Assets
IncreaseDecreaseInPrepaidDeferredExpenseAndOtherAssets
-3702000
CY2015 us-gaap Increase Decrease In Prepaid Deferred Expense And Other Assets
IncreaseDecreaseInPrepaidDeferredExpenseAndOtherAssets
-637000
CY2017 us-gaap Increase Decrease In Receivables
IncreaseDecreaseInReceivables
-2651000
CY2016 us-gaap Increase Decrease In Receivables
IncreaseDecreaseInReceivables
2525000
CY2015 us-gaap Increase Decrease In Receivables
IncreaseDecreaseInReceivables
-3247000
CY2017 us-gaap Increase Decrease In Restricted Cash
IncreaseDecreaseInRestrictedCash
1740000
CY2016 us-gaap Increase Decrease In Restricted Cash
IncreaseDecreaseInRestrictedCash
-66000
CY2015 us-gaap Increase Decrease In Restricted Cash
IncreaseDecreaseInRestrictedCash
1462000
CY2017 us-gaap Interest And Other Income
InterestAndOtherIncome
1015000
CY2016 us-gaap Interest And Other Income
InterestAndOtherIncome
793000
CY2015 us-gaap Interest And Other Income
InterestAndOtherIncome
535000
CY2017 us-gaap Interest Expense
InterestExpense
8565000
CY2016 us-gaap Interest Expense
InterestExpense
6487000
CY2015 us-gaap Interest Expense
InterestExpense
5200000
CY2017Q4 us-gaap Interest Payable Current
InterestPayableCurrent
12095000
CY2016Q4 us-gaap Interest Payable Current
InterestPayableCurrent
8990000
CY2017Q4 us-gaap Inventory Net
InventoryNet
CY2016Q4 us-gaap Inventory Net
InventoryNet
500000
CY2017Q4 us-gaap Liabilities And Stockholders Equity
LiabilitiesAndStockholdersEquity
178259000
CY2016Q4 us-gaap Liabilities And Stockholders Equity
LiabilitiesAndStockholdersEquity
89847000
CY2017Q4 us-gaap Liabilities Current
LiabilitiesCurrent
74836000
CY2016Q4 us-gaap Liabilities Current
LiabilitiesCurrent
54360000
CY2017Q4 us-gaap Line Of Credit
LineOfCredit
16750000
CY2016Q4 us-gaap Line Of Credit
LineOfCredit
22777000
CY2017Q4 us-gaap Lines Of Credit Current
LinesOfCreditCurrent
6464000
CY2016Q4 us-gaap Lines Of Credit Current
LinesOfCreditCurrent
CY2017Q4 us-gaap Long Term Debt
LongTermDebt
23000000
CY2017Q4 us-gaap Long Term Debt Maturities Repayments Of Principal In Year Five
LongTermDebtMaturitiesRepaymentsOfPrincipalInYearFive
2300000
CY2017Q4 us-gaap Long Term Debt Maturities Repayments Of Principal In Year Four
LongTermDebtMaturitiesRepaymentsOfPrincipalInYearFour
6900000
CY2017Q4 us-gaap Long Term Debt Maturities Repayments Of Principal In Year Three
LongTermDebtMaturitiesRepaymentsOfPrincipalInYearThree
6900000
CY2017Q4 us-gaap Long Term Debt Maturities Repayments Of Principal In Year Two
LongTermDebtMaturitiesRepaymentsOfPrincipalInYearTwo
6900000
CY2017 us-gaap Net Cash Provided By Used In Financing Activities
NetCashProvidedByUsedInFinancingActivities
135703000
CY2016 us-gaap Net Cash Provided By Used In Financing Activities
NetCashProvidedByUsedInFinancingActivities
23304000
CY2015 us-gaap Net Cash Provided By Used In Financing Activities
NetCashProvidedByUsedInFinancingActivities
5479000
CY2017 us-gaap Net Cash Provided By Used In Investing Activities
NetCashProvidedByUsedInInvestingActivities
-66382000
CY2016 us-gaap Net Cash Provided By Used In Investing Activities
NetCashProvidedByUsedInInvestingActivities
23339000
CY2015 us-gaap Net Cash Provided By Used In Investing Activities
NetCashProvidedByUsedInInvestingActivities
-18004000
CY2017 us-gaap Net Cash Provided By Used In Operating Activities
NetCashProvidedByUsedInOperatingActivities
-41143000
CY2016 us-gaap Net Cash Provided By Used In Operating Activities
NetCashProvidedByUsedInOperatingActivities
-53438000
CY2015 us-gaap Net Cash Provided By Used In Operating Activities
NetCashProvidedByUsedInOperatingActivities
-13116000
CY2015 us-gaap Net Income Loss
NetIncomeLoss
-43019000
CY2016 us-gaap Net Income Loss
NetIncomeLoss
-55144000
CY2017 us-gaap Net Income Loss
NetIncomeLoss
-65782000
CY2017Q1 us-gaap Net Income Loss
NetIncomeLoss
-14219000
CY2017Q2 us-gaap Net Income Loss
NetIncomeLoss
-16886000
CY2017Q3 us-gaap Net Income Loss
NetIncomeLoss
-15134000
CY2017Q4 us-gaap Net Income Loss
NetIncomeLoss
-19543000
CY2016Q1 us-gaap Net Income Loss
NetIncomeLoss
-22832000
CY2016Q2 us-gaap Net Income Loss
NetIncomeLoss
-16281000
CY2016Q3 us-gaap Net Income Loss
NetIncomeLoss
-11528000
CY2016Q4 us-gaap Net Income Loss
NetIncomeLoss
-4503000
CY2017Q4 us-gaap Notes Payable Current
NotesPayableCurrent
28682000
CY2016Q4 us-gaap Notes Payable Current
NotesPayableCurrent
28243000
CY2017 us-gaap Operating Income Loss
OperatingIncomeLoss
-57411000
CY2016 us-gaap Operating Income Loss
OperatingIncomeLoss
-48607000
CY2015 us-gaap Operating Income Loss
OperatingIncomeLoss
-39444000
CY2017Q4 us-gaap Operating Leases Future Minimum Payments Due
OperatingLeasesFutureMinimumPaymentsDue
6153000
CY2017Q4 us-gaap Operating Leases Future Minimum Payments Due Current
OperatingLeasesFutureMinimumPaymentsDueCurrent
1169000
CY2017Q4 us-gaap Operating Leases Future Minimum Payments Due In Five Years
OperatingLeasesFutureMinimumPaymentsDueInFiveYears
490000
CY2017Q4 us-gaap Operating Leases Future Minimum Payments Due In Four Years
OperatingLeasesFutureMinimumPaymentsDueInFourYears
479000
CY2017Q4 us-gaap Operating Leases Future Minimum Payments Due In Three Years
OperatingLeasesFutureMinimumPaymentsDueInThreeYears
862000
CY2017Q4 us-gaap Operating Leases Future Minimum Payments Due In Two Years
OperatingLeasesFutureMinimumPaymentsDueInTwoYears
1154000
CY2017Q4 us-gaap Operating Leases Future Minimum Payments Due Thereafter
OperatingLeasesFutureMinimumPaymentsDueThereafter
1999000
CY2017 us-gaap Operating Leases Rent Expense Net
OperatingLeasesRentExpenseNet
617000
CY2016 us-gaap Operating Leases Rent Expense Net
OperatingLeasesRentExpenseNet
721000
CY2015 us-gaap Operating Leases Rent Expense Net
OperatingLeasesRentExpenseNet
664000
CY2017Q4 us-gaap Other Accrued Liabilities Current
OtherAccruedLiabilitiesCurrent
2234000
CY2016Q4 us-gaap Other Accrued Liabilities Current
OtherAccruedLiabilitiesCurrent
1981000
CY2017Q4 us-gaap Other Assets Noncurrent
OtherAssetsNoncurrent
2027000
CY2016Q4 us-gaap Other Assets Noncurrent
OtherAssetsNoncurrent
3813000
CY2015 us-gaap Other Comprehensive Income Loss Net Of Tax
OtherComprehensiveIncomeLossNetOfTax
-76000
CY2016 us-gaap Other Comprehensive Income Loss Net Of Tax
OtherComprehensiveIncomeLossNetOfTax
194000
CY2017 us-gaap Other Comprehensive Income Loss Net Of Tax
OtherComprehensiveIncomeLossNetOfTax
-231000
CY2017 us-gaap Other Comprehensive Income Unrealized Holding Gain Loss On Securities Arising During Period Net Of Tax
OtherComprehensiveIncomeUnrealizedHoldingGainLossOnSecuritiesArisingDuringPeriodNetOfTax
-231000
CY2016 us-gaap Other Comprehensive Income Unrealized Holding Gain Loss On Securities Arising During Period Net Of Tax
OtherComprehensiveIncomeUnrealizedHoldingGainLossOnSecuritiesArisingDuringPeriodNetOfTax
194000
CY2015 us-gaap Other Comprehensive Income Unrealized Holding Gain Loss On Securities Arising During Period Net Of Tax
OtherComprehensiveIncomeUnrealizedHoldingGainLossOnSecuritiesArisingDuringPeriodNetOfTax
-76000
CY2017 us-gaap Payments To Acquire Available For Sale Securities Debt
PaymentsToAcquireAvailableForSaleSecuritiesDebt
107787000
CY2016 us-gaap Payments To Acquire Available For Sale Securities Debt
PaymentsToAcquireAvailableForSaleSecuritiesDebt
14106000
CY2015 us-gaap Payments To Acquire Available For Sale Securities Debt
PaymentsToAcquireAvailableForSaleSecuritiesDebt
53830000
CY2017 us-gaap Payments To Acquire Productive Assets
PaymentsToAcquireProductiveAssets
328000
CY2016 us-gaap Payments To Acquire Productive Assets
PaymentsToAcquireProductiveAssets
5277000
CY2015 us-gaap Payments To Acquire Productive Assets
PaymentsToAcquireProductiveAssets
5122000
CY2017Q4 us-gaap Preferred Stock Par Or Stated Value Per Share
PreferredStockParOrStatedValuePerShare
0.001
CY2016Q4 us-gaap Preferred Stock Par Or Stated Value Per Share
PreferredStockParOrStatedValuePerShare
0.001
CY2017Q4 us-gaap Preferred Stock Shares Authorized
PreferredStockSharesAuthorized
5000000
CY2016Q4 us-gaap Preferred Stock Shares Authorized
PreferredStockSharesAuthorized
5000000
CY2017Q4 us-gaap Preferred Stock Shares Issued
PreferredStockSharesIssued
0
CY2016Q4 us-gaap Preferred Stock Shares Issued
PreferredStockSharesIssued
0
CY2017Q4 us-gaap Preferred Stock Shares Outstanding
PreferredStockSharesOutstanding
0
CY2016Q4 us-gaap Preferred Stock Shares Outstanding
PreferredStockSharesOutstanding
0
CY2017Q4 us-gaap Preferred Stock Value
PreferredStockValue
CY2016Q4 us-gaap Preferred Stock Value
PreferredStockValue
CY2017Q4 us-gaap Prepaid Expense And Other Assets Current
PrepaidExpenseAndOtherAssetsCurrent
1381000
CY2016Q4 us-gaap Prepaid Expense And Other Assets Current
PrepaidExpenseAndOtherAssetsCurrent
1438000
CY2017Q1 us-gaap Proceeds From Issuance Of Common Stock
ProceedsFromIssuanceOfCommonStock
47750000
CY2017Q3 us-gaap Proceeds From Issuance Of Common Stock
ProceedsFromIssuanceOfCommonStock
86250000
CY2017 us-gaap Proceeds From Issuance Of Common Stock
ProceedsFromIssuanceOfCommonStock
134000000
CY2016 us-gaap Proceeds From Issuance Of Common Stock
ProceedsFromIssuanceOfCommonStock
CY2015 us-gaap Proceeds From Issuance Of Common Stock
ProceedsFromIssuanceOfCommonStock
CY2017 us-gaap Proceeds From Lines Of Credit
ProceedsFromLinesOfCredit
CY2016 us-gaap Proceeds From Lines Of Credit
ProceedsFromLinesOfCredit
22658000
CY2015 us-gaap Proceeds From Lines Of Credit
ProceedsFromLinesOfCredit
CY2017 us-gaap Proceeds From Sale And Maturity Of Available For Sale Securities
ProceedsFromSaleAndMaturityOfAvailableForSaleSecurities
43461000
CY2016 us-gaap Proceeds From Sale And Maturity Of Available For Sale Securities
ProceedsFromSaleAndMaturityOfAvailableForSaleSecurities
42652000
CY2015 us-gaap Proceeds From Sale And Maturity Of Available For Sale Securities
ProceedsFromSaleAndMaturityOfAvailableForSaleSecurities
42410000
CY2017 us-gaap Proceeds From Sale Of Furniture And Fixtures
ProceedsFromSaleOfFurnitureAndFixtures
12000
CY2016 us-gaap Proceeds From Sale Of Furniture And Fixtures
ProceedsFromSaleOfFurnitureAndFixtures
4000
CY2015 us-gaap Proceeds From Sale Of Furniture And Fixtures
ProceedsFromSaleOfFurnitureAndFixtures
CY2017 us-gaap Proceeds From Stock Options Exercised
ProceedsFromStockOptionsExercised
1581000
CY2016 us-gaap Proceeds From Stock Options Exercised
ProceedsFromStockOptionsExercised
317000
CY2015 us-gaap Proceeds From Stock Options Exercised
ProceedsFromStockOptionsExercised
5479000
CY2017Q4 us-gaap Property Plant And Equipment Gross
PropertyPlantAndEquipmentGross
14873000
CY2016Q4 us-gaap Property Plant And Equipment Gross
PropertyPlantAndEquipmentGross
14839000
CY2017Q4 us-gaap Property Plant And Equipment Net
PropertyPlantAndEquipmentNet
9546000
CY2016Q4 us-gaap Property Plant And Equipment Net
PropertyPlantAndEquipmentNet
9922000
CY2017Q4 us-gaap Receivables Net Current
ReceivablesNetCurrent
6117000
CY2016Q4 us-gaap Receivables Net Current
ReceivablesNetCurrent
8768000
CY2017 us-gaap Reclassification From Accumulated Other Comprehensive Income Current Period Before Tax
ReclassificationFromAccumulatedOtherComprehensiveIncomeCurrentPeriodBeforeTax
-1000
CY2016 us-gaap Reclassification From Accumulated Other Comprehensive Income Current Period Before Tax
ReclassificationFromAccumulatedOtherComprehensiveIncomeCurrentPeriodBeforeTax
11000
CY2017 us-gaap Research And Development Expense
ResearchAndDevelopmentExpense
66962000
CY2016 us-gaap Research And Development Expense
ResearchAndDevelopmentExpense
61008000
CY2015 us-gaap Research And Development Expense
ResearchAndDevelopmentExpense
72758000
CY2017Q4 us-gaap Restricted Cash And Cash Equivalents At Carrying Value
RestrictedCashAndCashEquivalentsAtCarryingValue
3286000
CY2016Q4 us-gaap Restricted Cash And Cash Equivalents At Carrying Value
RestrictedCashAndCashEquivalentsAtCarryingValue
1546000
CY2017Q4 us-gaap Retained Earnings Accumulated Deficit
RetainedEarningsAccumulatedDeficit
-631843000
CY2016Q4 us-gaap Retained Earnings Accumulated Deficit
RetainedEarningsAccumulatedDeficit
-566061000
CY2017 us-gaap Revenues
Revenues
25186000
CY2016 us-gaap Revenues
Revenues
26353000
CY2015 us-gaap Revenues
Revenues
48257000
CY2017 us-gaap Royalty Expense
RoyaltyExpense
560000
CY2016 us-gaap Royalty Expense
RoyaltyExpense
402000
CY2015 us-gaap Royalty Expense
RoyaltyExpense
528000
CY2017 us-gaap Royalty Revenue
RoyaltyRevenue
10543000
CY2016 us-gaap Royalty Revenue
RoyaltyRevenue
9682000
CY2015 us-gaap Royalty Revenue
RoyaltyRevenue
2386000
CY2017 us-gaap Sales Revenue Goods Net
SalesRevenueGoodsNet
1501000
CY2016 us-gaap Sales Revenue Goods Net
SalesRevenueGoodsNet
2269000
CY2015 us-gaap Sales Revenue Goods Net
SalesRevenueGoodsNet
6291000
CY2017 us-gaap Sales Revenue Net
SalesRevenueNet
25186000
CY2016 us-gaap Sales Revenue Net
SalesRevenueNet
26353000
CY2015 us-gaap Sales Revenue Net
SalesRevenueNet
48257000
CY2017Q1 us-gaap Sales Revenue Net
SalesRevenueNet
9437000
CY2017Q2 us-gaap Sales Revenue Net
SalesRevenueNet
3099000
CY2017Q3 us-gaap Sales Revenue Net
SalesRevenueNet
8760000
CY2017Q4 us-gaap Sales Revenue Net
SalesRevenueNet
3890000
CY2016Q1 us-gaap Sales Revenue Net
SalesRevenueNet
4820000
CY2016Q2 us-gaap Sales Revenue Net
SalesRevenueNet
4787000
CY2016Q3 us-gaap Sales Revenue Net
SalesRevenueNet
7763000
CY2016Q4 us-gaap Sales Revenue Net
SalesRevenueNet
8983000
CY2017 us-gaap Selling General And Administrative Expense
SellingGeneralAndAdministrativeExpense
13933000
CY2016 us-gaap Selling General And Administrative Expense
SellingGeneralAndAdministrativeExpense
11253000
CY2015 us-gaap Selling General And Administrative Expense
SellingGeneralAndAdministrativeExpense
13047000
CY2017 us-gaap Share Based Compensation
ShareBasedCompensation
12621000
CY2016 us-gaap Share Based Compensation
ShareBasedCompensation
8487000
CY2015 us-gaap Share Based Compensation
ShareBasedCompensation
9705000
CY2017 us-gaap Share Based Compensation Arrangement By Share Based Payment Award Options Forfeitures In Period
ShareBasedCompensationArrangementByShareBasedPaymentAwardOptionsForfeituresInPeriod
395000
CY2017 us-gaap Share Based Compensation Arrangement By Share Based Payment Award Options Grants In Period Gross
ShareBasedCompensationArrangementByShareBasedPaymentAwardOptionsGrantsInPeriodGross
3915000
CY2017 us-gaap Share Based Compensation Arrangement By Share Based Payment Award Options Grants In Period Weighted Average Grant Date Fair Value
ShareBasedCompensationArrangementByShareBasedPaymentAwardOptionsGrantsInPeriodWeightedAverageGrantDateFairValue
3.63
CY2017Q4 us-gaap Share Based Compensation Arrangement By Share Based Payment Award Options Vested And Expected To Vest Outstanding Number
ShareBasedCompensationArrangementByShareBasedPaymentAwardOptionsVestedAndExpectedToVestOutstandingNumber
13267000
CY2017Q4 us-gaap Share Based Compensation Arrangement By Share Based Payment Award Options Vested And Expected To Vest Outstanding Weighted Average Exercise Price
ShareBasedCompensationArrangementByShareBasedPaymentAwardOptionsVestedAndExpectedToVestOutstandingWeightedAverageExercisePrice
5.95
CY2017 us-gaap Share Based Compensation Shares Authorized Under Stock Option Plans Exercise Price Range Lower Range Limit
ShareBasedCompensationSharesAuthorizedUnderStockOptionPlansExercisePriceRangeLowerRangeLimit
0
CY2017Q4 us-gaap Share Based Compensation Shares Authorized Under Stock Option Plans Exercise Price Range Number Of Exercisable Options
ShareBasedCompensationSharesAuthorizedUnderStockOptionPlansExercisePriceRangeNumberOfExercisableOptions
7250000
CY2017Q4 us-gaap Share Based Compensation Shares Authorized Under Stock Option Plans Exercise Price Range Number Of Outstanding Options
ShareBasedCompensationSharesAuthorizedUnderStockOptionPlansExercisePriceRangeNumberOfOutstandingOptions
14452000
CY2017 us-gaap Share Based Compensation Shares Authorized Under Stock Option Plans Exercise Price Range Upper Range Limit
ShareBasedCompensationSharesAuthorizedUnderStockOptionPlansExercisePriceRangeUpperRangeLimit
18
CY2017Q4 us-gaap Sharebased Compensation Arrangement By Sharebased Payment Award Options Exercisable Intrinsic Value1
SharebasedCompensationArrangementBySharebasedPaymentAwardOptionsExercisableIntrinsicValue1
7631000
CY2016Q4 us-gaap Sharebased Compensation Arrangement By Sharebased Payment Award Options Nonvested Number Of Shares
SharebasedCompensationArrangementBySharebasedPaymentAwardOptionsNonvestedNumberOfShares
5598000
CY2017Q4 us-gaap Sharebased Compensation Arrangement By Sharebased Payment Award Options Nonvested Number Of Shares
SharebasedCompensationArrangementBySharebasedPaymentAwardOptionsNonvestedNumberOfShares
7202000
CY2017 us-gaap Sharebased Compensation Arrangement By Sharebased Payment Award Options Nonvested Options Forfeited Weighted Average Grant Date Fair Value
SharebasedCompensationArrangementBySharebasedPaymentAwardOptionsNonvestedOptionsForfeitedWeightedAverageGrantDateFairValue
5.84
CY2016Q4 us-gaap Sharebased Compensation Arrangement By Sharebased Payment Award Options Nonvested Weighted Average Grant Date Fair Value
SharebasedCompensationArrangementBySharebasedPaymentAwardOptionsNonvestedWeightedAverageGrantDateFairValue
5.40
CY2017Q4 us-gaap Sharebased Compensation Arrangement By Sharebased Payment Award Options Nonvested Weighted Average Grant Date Fair Value
SharebasedCompensationArrangementBySharebasedPaymentAwardOptionsNonvestedWeightedAverageGrantDateFairValue
4.56
CY2017 us-gaap Sharebased Compensation Arrangement By Sharebased Payment Award Options Vested And Expected To Vest Outstanding Weighted Average Remaining Contractual Term1
SharebasedCompensationArrangementBySharebasedPaymentAwardOptionsVestedAndExpectedToVestOutstandingWeightedAverageRemainingContractualTerm1
P6Y292D
CY2017 us-gaap Sharebased Compensation Arrangement By Sharebased Payment Award Options Vested In Period Fair Value1
SharebasedCompensationArrangementBySharebasedPaymentAwardOptionsVestedInPeriodFairValue1
9310000
CY2016 us-gaap Sharebased Compensation Arrangement By Sharebased Payment Award Options Vested In Period Fair Value1
SharebasedCompensationArrangementBySharebasedPaymentAwardOptionsVestedInPeriodFairValue1
6380000
CY2015 us-gaap Sharebased Compensation Arrangement By Sharebased Payment Award Options Vested In Period Fair Value1
SharebasedCompensationArrangementBySharebasedPaymentAwardOptionsVestedInPeriodFairValue1
4492000
CY2017 us-gaap Sharebased Compensation Arrangement By Sharebased Payment Award Options Vested Number Of Shares
SharebasedCompensationArrangementBySharebasedPaymentAwardOptionsVestedNumberOfShares
1916000
CY2017 us-gaap Sharebased Compensation Arrangement By Sharebased Payment Award Options Vested Weighted Average Grant Date Fair Value
SharebasedCompensationArrangementBySharebasedPaymentAwardOptionsVestedWeightedAverageGrantDateFairValue
4.86
CY2017Q4 us-gaap Sharebased Compensation Shares Authorized Under Stock Option Plans Exercise Price Range Exercisable Options Weighted Average Exercise Price1
SharebasedCompensationSharesAuthorizedUnderStockOptionPlansExercisePriceRangeExercisableOptionsWeightedAverageExercisePrice1
5.69
CY2017Q4 us-gaap Sharebased Compensation Shares Authorized Under Stock Option Plans Exercise Price Range Outstanding Options Weighted Average Exercise Price Beginning Balance1
SharebasedCompensationSharesAuthorizedUnderStockOptionPlansExercisePriceRangeOutstandingOptionsWeightedAverageExercisePriceBeginningBalance1
6.06
CY2017 us-gaap Sharebased Compensation Shares Authorized Under Stock Option Plans Exercise Price Range Outstanding Options Weighted Average Remaining Contractual Term2
SharebasedCompensationSharesAuthorizedUnderStockOptionPlansExercisePriceRangeOutstandingOptionsWeightedAverageRemainingContractualTerm2
P6Y292D
CY2017Q1 us-gaap Shares Issued Price Per Share
SharesIssuedPricePerShare
8.50
CY2017Q3 us-gaap Shares Issued Price Per Share
SharesIssuedPricePerShare
5.15
CY2017Q1 us-gaap Stock Issued During Period Shares New Issues
StockIssuedDuringPeriodSharesNewIssues
6061000
CY2017Q3 us-gaap Stock Issued During Period Shares New Issues
StockIssuedDuringPeriodSharesNewIssues
17864000
CY2015 us-gaap Stock Issued During Period Value Employee Stock Purchase Plan
StockIssuedDuringPeriodValueEmployeeStockPurchasePlan
355000
CY2016 us-gaap Stock Issued During Period Value Employee Stock Purchase Plan
StockIssuedDuringPeriodValueEmployeeStockPurchasePlan
329000
CY2017 us-gaap Stock Issued During Period Value Employee Stock Purchase Plan
StockIssuedDuringPeriodValueEmployeeStockPurchasePlan
345000
CY2017 us-gaap Stock Issued During Period Value New Issues
StockIssuedDuringPeriodValueNewIssues
134000000
CY2015 us-gaap Stock Issued During Period Value Stock Options Exercised
StockIssuedDuringPeriodValueStockOptionsExercised
5124000
CY2016 us-gaap Stock Issued During Period Value Stock Options Exercised
StockIssuedDuringPeriodValueStockOptionsExercised
-12000
CY2017 us-gaap Stock Issued During Period Value Stock Options Exercised
StockIssuedDuringPeriodValueStockOptionsExercised
1236000
CY2014Q4 us-gaap Stockholders Equity
StockholdersEquity
75635000
CY2015Q4 us-gaap Stockholders Equity
StockholdersEquity
47724000
CY2016Q4 us-gaap Stockholders Equity
StockholdersEquity
1578000
CY2017Q4 us-gaap Stockholders Equity
StockholdersEquity
83767000
CY2017Q4 us-gaap Taxes Payable Current
TaxesPayableCurrent
148000
CY2016 us-gaap Unrecognized Tax Benefits Decreases Resulting From Prior Period Tax Positions
UnrecognizedTaxBenefitsDecreasesResultingFromPriorPeriodTaxPositions
CY2017Q4 us-gaap Unrecognized Tax Benefits Income Tax Penalties And Interest Accrued
UnrecognizedTaxBenefitsIncomeTaxPenaltiesAndInterestAccrued
0
CY2016Q4 us-gaap Unrecognized Tax Benefits Income Tax Penalties And Interest Accrued
UnrecognizedTaxBenefitsIncomeTaxPenaltiesAndInterestAccrued
0
CY2015Q4 us-gaap Unrecognized Tax Benefits Income Tax Penalties And Interest Accrued
UnrecognizedTaxBenefitsIncomeTaxPenaltiesAndInterestAccrued
0
CY2015 us-gaap Weighted Average Number Of Diluted Shares Outstanding
WeightedAverageNumberOfDilutedSharesOutstanding
72901000
CY2016Q4 us-gaap Taxes Payable Current
TaxesPayableCurrent
56000
CY2016Q4 us-gaap Unrecognized Tax Benefits
UnrecognizedTaxBenefits
4255000
CY2015Q4 us-gaap Unrecognized Tax Benefits
UnrecognizedTaxBenefits
3085000
CY2017Q4 us-gaap Unrecognized Tax Benefits
UnrecognizedTaxBenefits
4750000
CY2017 us-gaap Unrecognized Tax Benefits Decreases Resulting From Prior Period Tax Positions
UnrecognizedTaxBenefitsDecreasesResultingFromPriorPeriodTaxPositions
CY2017 us-gaap Unrecognized Tax Benefits Increases Resulting From Current Period Tax Positions
UnrecognizedTaxBenefitsIncreasesResultingFromCurrentPeriodTaxPositions
495000
CY2016 us-gaap Unrecognized Tax Benefits Increases Resulting From Current Period Tax Positions
UnrecognizedTaxBenefitsIncreasesResultingFromCurrentPeriodTaxPositions
1170000
CY2017 us-gaap Unrecognized Tax Benefits Increases Resulting From Prior Period Tax Positions
UnrecognizedTaxBenefitsIncreasesResultingFromPriorPeriodTaxPositions
CY2016 us-gaap Unrecognized Tax Benefits Increases Resulting From Prior Period Tax Positions
UnrecognizedTaxBenefitsIncreasesResultingFromPriorPeriodTaxPositions
CY2017 us-gaap Use Of Estimates
UseOfEstimates
<div style="display: inline; font-family: times new roman; font-size: 10pt"><div style="display: inline; font-family: times new roman; font-size: 10pt"><div style=" font-size: 10pt; margin: 0pt 0 0pt 11.5pt"><div style="display: inline; font-weight: bold;"><div style="display: inline; font-style: italic;">Use of Estimates</div></div></div> <div style=" font-size: 10pt; margin: 0pt 0 0pt 11.5pt">&nbsp;</div> <div style=" font-size: 10pt; text-indent: 27pt; margin: 0pt 0">The preparation of financial statements in conformity with U.S. GAAP requires the Company to make estimates and assumptions that affect the amounts reported in the financial statements. Actual results could differ from those estimates.&nbsp;&nbsp;</div></div></div>
CY2017 us-gaap Weighted Average Number Of Diluted Shares Outstanding
WeightedAverageNumberOfDilutedSharesOutstanding
84451000
CY2016 us-gaap Weighted Average Number Of Diluted Shares Outstanding
WeightedAverageNumberOfDilutedSharesOutstanding
73699000

Files In Submission

Name View Source Status
0001171843-18-001855-index-headers.html Edgar Link pending
0001171843-18-001855-index.html Edgar Link pending
0001171843-18-001855.txt Edgar Link pending
0001171843-18-001855-xbrl.zip Edgar Link pending
bcrx-20171231.xml Edgar Link completed
bcrx-20171231.xsd Edgar Link pending
bcrx-20171231_cal.xml Edgar Link unprocessable
bcrx-20171231_def.xml Edgar Link unprocessable
bcrx-20171231_lab.xml Edgar Link unprocessable
bcrx-20171231_pre.xml Edgar Link unprocessable
exh1088_01.jpg Edgar Link pending
exh_1088.htm Edgar Link pending
exh_21.htm Edgar Link pending
exh_23.htm Edgar Link pending
exh_311.htm Edgar Link pending
exh_312.htm Edgar Link pending
exh_321.htm Edgar Link pending
exh_322.htm Edgar Link pending
f10k_022718p.htm Edgar Link pending
FilingSummary.xml Edgar Link unprocessable
Financial_Report.xlsx Edgar Link pending
graph_1.jpg Edgar Link pending
R1.htm Edgar Link pending
R10.htm Edgar Link pending
R11.htm Edgar Link pending
R12.htm Edgar Link pending
R13.htm Edgar Link pending
R14.htm Edgar Link pending
R15.htm Edgar Link pending
R16.htm Edgar Link pending
R17.htm Edgar Link pending
R18.htm Edgar Link pending
R19.htm Edgar Link pending
R2.htm Edgar Link pending
R20.htm Edgar Link pending
R21.htm Edgar Link pending
R22.htm Edgar Link pending
R23.htm Edgar Link pending
R24.htm Edgar Link pending
R25.htm Edgar Link pending
R26.htm Edgar Link pending
R27.htm Edgar Link pending
R28.htm Edgar Link pending
R29.htm Edgar Link pending
R3.htm Edgar Link pending
R30.htm Edgar Link pending
R31.htm Edgar Link pending
R32.htm Edgar Link pending
R33.htm Edgar Link pending
R34.htm Edgar Link pending
R35.htm Edgar Link pending
R36.htm Edgar Link pending
R37.htm Edgar Link pending
R38.htm Edgar Link pending
R39.htm Edgar Link pending
R4.htm Edgar Link pending
R40.htm Edgar Link pending
R41.htm Edgar Link pending
R42.htm Edgar Link pending
R43.htm Edgar Link pending
R44.htm Edgar Link pending
R45.htm Edgar Link pending
R46.htm Edgar Link pending
R47.htm Edgar Link pending
R48.htm Edgar Link pending
R49.htm Edgar Link pending
R5.htm Edgar Link pending
R50.htm Edgar Link pending
R51.htm Edgar Link pending
R52.htm Edgar Link pending
R53.htm Edgar Link pending
R54.htm Edgar Link pending
R55.htm Edgar Link pending
R56.htm Edgar Link pending
R6.htm Edgar Link pending
R7.htm Edgar Link pending
R8.htm Edgar Link pending
R9.htm Edgar Link pending
report.css Edgar Link pending
Show.js Edgar Link pending